Hayek T, Fuhrman B, Levy Y, Aviram M, Brook J G
Lipid Research Laboratory, Rambam Medical Center, Haifa.
Harefuah. 1989 Sep;117(5-6):122-6.
Intralipid, used for intravenous alimentation and containing triglyceride emulsion particles and phospholipid liposomes, has been shown to induce regression of atherosclerosis in experimental animals. Intravenous infusions of Intralipid were given to 2 patients with severe familial hypercholesterolemia refractory to conventional therapy, and to control subjects. Intracellular cholesterol esterification was inhibited in macrophages incubated with serum taken during infusions as compared to the preinfusion state, with maximal effect after 6 h of infusion. A significant decrease in platelet aggregation was also demonstrated in both groups, which persisted for 18 h after infusion. We conclude that infusion of Intralipid may have anti-atherogenic effects and plan to use it in patients with severe atherosclerosis.
英脱利匹特用于静脉营养,含有甘油三酯乳剂颗粒和磷脂脂质体,已被证明可使实验动物的动脉粥样硬化消退。对2例常规治疗无效的重度家族性高胆固醇血症患者及对照受试者进行了英脱利匹特静脉输注。与输注前状态相比,输注期间采集的血清孵育的巨噬细胞内胆固醇酯化受到抑制,输注6小时后效果最大。两组患者的血小板聚集也显著降低,输注后持续18小时。我们得出结论,输注英脱利匹特可能具有抗动脉粥样硬化作用,并计划将其用于重度动脉粥样硬化患者。